Lung cancer patients' own immune cells may shrink tumors in new trial
NCT ID NCT07560111
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This phase II study tests a treatment made from a patient's own tumor-fighting immune cells (TILs) for non-small cell lung cancer. About 28 adults aged 18-70 whose cancer has not responded to standard treatments will receive their own expanded TILs. The goal is to see if this approach can shrink tumors and delay cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.